CHEVY CHASE, MD. September 23, 2013 — Metabiomics is pleased to announce the addition of four new members to the management team and advisory board. Dr. Louis Korman has joined the Metabiomics management team as Chief Medical Officer. Dr. Robert Hardi, Dr. Jeff Baybick, and Dr. Paul DeRidder have joined the advisory board.
Dr. Korman, Dr. Hardi and Dr. Baybick, who are all experienced, nationally engaged and actively practicing clinicians at Capital Digestive Care and the Metropolitan Gastroenterology Group, have collectively signed a collaboration agreement with Metabiomics to support the development and execution of two clinical studies (MB-01 and MB-02) to expand the clinical evidence of safety, efficacy and clinical utility of our colon polyp and colorectal cancer test, and to advance the goal of convincing health care system stakeholders to support and advocate further development and commercialization. The scope of the collaboration includes both the clinical studies as well as management and advisory roles to support translational medicine and commercialization efforts.
Dr. DeRidder was instrumental in expanding Metabiomics’ global distribution channels and forging a strategic alliance with Kindstar Global, Wuhan China. Dr. ReRidder has joined the Metabiomics advisory board and will continue to act as our China liaison as well as contributing to business development efforts, and helping to identify and qualify potential R&D, regulatory, and reference lab partnering opportunities.
Louis Y. Korman, M.D. Chief Medical Officer
Dr. Korman has been a practicing gastroenterologist with the Metropolitan Gastroenterology Group since 1990. Dr. Korman received his training in Digestive Diseases at National Institutes of Health and has numerous publications and patents in basic and applied science. In addition to his clinical practice, he teaches gastroenterology and endoscopy in the Gastroenterology Training Program at Veterans Administration Hospital and Georgetown University Fellowship program. Dr. Korman is also a Principle Investigator in Chevy Chase Clinical Research, one of the largest clinical gastroenterology research programs in the Washington Metropolitan area.
Robert Hardi, M.D., Advisory Board Member
Dr. Hardi has been a practicing Gastroenterologist for 30 years. Since 1996 he has been the Medical Director and Principal Investigator of his practice’s dedicated research arm, which has successfully conducted more than 250 studies. His principal professional interests are inflammatory bowel diseases (he has served on the National Board of the Crohn’s and Colitis Foundation of America), clinical research, procedural sedation, colon cancer surveillance, and pancreatic and biliary disorders. He is Board Certified in both Internal Medicine and Gastroenterology and is a certified physician investigator (CPI). Dr. Hardi is also a board member and President Elect of of the Academy of Physicians in Clinical Research (APCR).
Jeffrey Baybick, M.D., Advisory Board Member
Dr. Baybick is the Medical Director and Chief Pathologist at Capital Digestive Care, LLC, which is one of the leading GI pathology laboratories in the nation. Dr. Baybick specializes in GI pathology and diagnosing these conditions and has a great interest in resolving many of the practical problems that a gastrointestinal pathologist deals with on a daily basis. Dr. Baybick is certified by the American Board of Pathology in anatomic and clinical pathology as well as cytopathology. Dr. Baybick originally founded the pathology laboratory as Bay Labs in January 2004 before joining with Capital Digestive Care. Under his direction, the high complexity CAP accredited and CLIA laboratory integrates seamlessly with all Capital Digestive Care facilities, ensuring optimal continuity of care for patients.
Paul A. DeRidder, MD, MBA, Advisory Board Member
Dr. DeRidder is a board-certified Urologist, past Chairman of the Section of Urology at St. Joseph Hospital in Orange, California, and Diplomat of The American College of Physician Executives. He was recently recognized as a Certified Physician Executive by the Certifying Commission in Medical Management. He has been a co-founder and CEO of several specialty management organizations, and was a co-founder and Board member of Urotherapies, Inc. As a healthcare entrepreneur and investor he has been an advisory board and board of directors member of several companies. He is presently a member of the Tech Coast Angels, Executive Committee, a Southern California group of investors in early stage companies.
Metabiomics Corporation is an early-stage, diagnostics company that is developing non-invasive screening tests for gastrointestinal and autoimmune diseases based on human microbiome biomarkers. The company has developed/licensed patented/patent-pending technology that integrates advances in microbial ecology, next-generation DNA sequencing, and computational systems biology. These innovations were developed over the past 10 years in collaboration with Dr. Patrick Gillevet, Vice President and Chief Scientific Officer of Metabiomics, at the Microbiome Analysis Center at George Mason University and many other clinical research partners at leading academic medical centers in the US and Canada. Metabiomics was formed in 2011 as a wholly owned subsidiary of BioSpherex LLC to focus on molecular diagnostic application of human microbiome research in translational medicine.
Metabiomics Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential results and future outcomes our clinical research and business plan; ability to discover biomarkers and diagnostic tests; our beliefs regarding the need for and value of molecular diagnostics; and the focus and attributes of the company’s product pipeline, including the ability of the company’s tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical and developmental studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and the timing thereof; unanticipated costs or delays in research and development efforts; the applicability of initial next generation sequencing studies to future results; the risk that we may not obtain or maintain reimbursement for diagnostic tests we may develop, both domestically and abroad; our ability to compete against third parties; the risks and uncertainties associated with the regulation of our tests by the FDA and other agencies abroad; and the other risks set forth in the company’s business plans and presentations. These forward- looking statements speak only as of the date hereof. Metabiomics disclaims any obligation to update these forward-looking statements.